Salix Pharmaceuticals vs. Ajanta Pharma: Rifaximin Patent Dispute Ends in Confidential Settlement
What would you like to do next?
Choose your path based on your current needs:
📋 Case Summary
| Case Name | Salix Pharmaceuticals, Inc. v. Ajanta Pharma Limited |
| Case Number | 1:25-cv-17780 (D.N.J.) |
| Court | District of New Jersey |
| Duration | Nov 2025 – Jan 2026 54 days |
| Outcome | Settled — Confidential Terms |
| Patents at Issue | |
| Accused Products | Ajanta’s Proposed Generic Rifaximin 550 mg Tablets |
Case Overview
The Parties
⚖️ Plaintiff
Subsidiary of Bausch Health Companies, holding commercial rights to Xifaxan® (rifaximin), a minimally absorbed oral antibiotic.
🛡️ Defendant
Mumbai-headquartered generic pharmaceutical manufacturer with a growing U.S. ANDA pipeline.
Patents at Issue
This landmark case involved three U.S. patents protecting Xifaxan® (rifaximin) 550 mg tablets. These patents collectively protect both the composition (polymorph forms) and method-of-use (IBS treatment protocols) dimensions of Xifaxan®.
- • US8193196B2 — Covers polymorphous forms of rifaximin, including specific crystalline forms and their production processes
- • US11779571B2 — Methods for treating IBS using rifaximin formulations
- • US11564912B2 — Additional IBS treatment method claims
Developing a generic drug or new formulation?
Check if your product might infringe these or related patents before launch.
The Verdict & Legal Analysis
Outcome
The case was resolved via a Stipulated Dismissal entered January 13, 2026, pursuant to a Confidential Settlement and License Agreement between all plaintiffs and Ajanta Pharma Limited. No damages were adjudicated. No injunctive relief was litigated to conclusion. The Clerk of Court was directed to close the case per the parties’ stipulation.
Key Legal Issues
The District of New Jersey, a specialized judicial venue for pharmaceutical IP disputes, presided over this Hatch-Waxman litigation. The rapid 54-day closure highlights the pharmaceutical industry’s preference for negotiated exits over protracted litigation, often involving a licensed entry date for generic challengers. This settlement contributes to the litigation data pattern surrounding Xifaxan’s patent portfolio without generating public legal analysis of validity or infringement.
Freedom to Operate (FTO) Analysis
This case highlights critical IP risks in pharmaceutical product development. Choose your next step:
📋 Understand This Case’s Impact
Learn about the specific risks and implications from this litigation.
- View all 3 related patents in this technology space
- See which companies are most active in rifaximin patents
- Understand polymorph and method-of-use claim patterns
🔍 Check My Product’s Risk
Run a comprehensive FTO analysis for your own drug formulation.
- Input your product description or chemical structure
- AI identifies potentially blocking pharmaceutical patents
- Get actionable risk assessment report
High Risk Area
Rifaximin formulations & IBS methods
3 Related Patents
Rifaximin 550 mg exclusivity
Settlement Pattern
Common in Hatch-Waxman cases
✅ Key Takeaways
Hatch-Waxman cases involving multi-patent portfolios (composition + method-of-use) consistently produce early settlements due to compounding litigation exposure.
Search related Hatch-Waxman case law →The 54-day resolution timeline indicates pre-litigation settlement engagement or immediate post-filing negotiations.
Explore pharmaceutical litigation trends →Frequently Asked Questions
Three U.S. patents were asserted: US8193196B2 (rifaximin polymorphs), US11779571B2 (IBS treatment methods), and US11564912B2 (IBS treatment methods), all protecting Xifaxan® 550 mg tablets.
The parties entered a Confidential Settlement and License Agreement, resulting in a Stipulated Dismissal filed January 13, 2026. Financial terms and any licensed entry date remain confidential.
Each settled Hatch-Waxman challenge without an invalidity ruling strengthens the practical enforceability of Salix’s patent portfolio, signaling continued litigation risk for future generic challengers of Xifaxan® 550 mg.
Ready to Strengthen Your Patent Strategy?
Join 18,000+ IP professionals using PatSnap Eureka to conduct prior art searches, draft patents, and analyse competitive landscapes with AI-powered precision.
References
- United States District Court for the District of New Jersey — Case 1:25-cv-17780
- U.S. Patent and Trademark Office — Patent Center
- U.S. Food & Drug Administration — Orange Book
- Cornell Legal Information Institute — Hatch-Waxman Act
- PatSnap — IP Intelligence for Pharma & Biotech
This article is for informational purposes only and does not constitute legal advice. All case information is drawn from publicly available court records. For platform capabilities, visit PatSnap.